Clinical trials: Movement Abnormalities
Tourette's Disorder (TD)
Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder
To evaluate the long-term efficacy of oral aripiprazole in pediatric participants for the treatment of Tourette's Disorder (TD).
- Trial name
- NCT03661983
- Testing
- Aripiprazole
- Where
- 42 sites in United States, Canada and 1 more
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Early-stage Parkinson's Disease
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants…
- Trial name
- ORCHESTRA (NCT04658186)
- Testing
- UCB0599
- Where
- 115 sites in United States, Canada and 7 more
- Volunteers
- 496 people
- Sponsor
- UCB Biopharma SRL
Parkinson Disease
Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor
Demonstrate safety and efficacy of TAPS delivered by a Cala device as a treatment for action tremor in subjects with Parkinson's disease hand tremor
- Trial name
- NCT05012579
- Testing
- Cala Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cala Health, Inc.
Huntington Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
WVE-HDSNP2-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120102 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism…
- Trial name
- NCT04617860
- Testing
- WVE-120102
- Where
- 20 sites in Australia, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Wave Life Sciences USA, Inc.
Parkinson Disease
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank…
- Trial name
- NCT05766813
- Testing
- Lenrispodun
- Where
- 35 sites in United States
- Volunteers
- 79 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Parkinson Disease
A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
This is a Phase 1b study investigating the safety and tolerability of IRl790 as adjunct therapy in patients with Parkinson disease. IRL790/placebo is taken for 28 days.
- Trial name
- NCT03531060
- Testing
- IRL790
- Volunteers
- 15 people
- Sponsor
- Integrative Research Laboratories AB
Parkinson's Disease, Restless Leg Syndrome
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole tablets,0.25 mg, to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fed conditions using a single dose, randomized, 2-treatment…
- Trial name
- NCT00674310
- Testing
- Ropinirole Hydrochloride
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Idiopathic Parkinson's Disease
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
The purpose of this double blind study is to determine whether CERE-120 (adeno-associated virus serotype 2 [AAV2]-neurturin [NTN]) is effective and safe in the treatment of patients with idiopathic Parkinson's Disease.
- Trial name
- NCT00400634
- Testing
- CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- Sangamo Therapeutics
Essential Tremor, Parkinson Disease
Pilot Study of the Felix System in Patients With Essential Tremor and Parkinson's Tremor
A prospective, open-label, multi-center pilot study designed to evaluate the safety and effectiveness of the Felix system in the relief of upper limb tremors in adults with essential tremor and Parkinson's disease.
- Trial name
- NCT05842434
- Testing
- Felix NeuroAI Wristband
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Fasikl Inc.
Parkinson Disease
Brain Stimulation for Patients With Parkinson Disease
The aim of this crossover study is to investigate the efficacy of non-invasive brain stimulation (transcranial pulse stimulation; TPS) in adults with Parkinson Disease (PD).
- Trial name
- NCT04333511
- Testing
- TPS (NEUROLITH)
- Where
- Austria
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Storz Medical AG
Wilson Disease
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
- Trial name
- NCT04573309
- Testing
- ALXN1840
- Where
- 3 sites in United States, New Zealand and 1 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Huntington Disease
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
- Trial name
- NCT05358717
- Testing
- PTC518
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease
A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover comparative Pharmacokinetics study of WD-1603 extended-release carbidopa/levodopa tablets in normal, healthy, adult human…
- Trial name
- NCT04553978
- Testing
- WD-1603
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
Parkinson Disease
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease
The primary purpose of this study is to determine whether sumanirole, at three different dose levels, is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease
- Trial name
- NCT00058838
- Testing
- sumanirole
- Where
- 134 sites in United States, Argentina and 12 more
- Volunteers
- 854 people
- Sponsor
- Pfizer
Essential Tremor, Parkinson Disease
The Essential Tremor (ET) and Parkinson Disease (PD) Tremor Acute Stimulation Study
The current study is designed to test the hypothesis that targeted electrical stimulation will result in upper limb tremor reduction in ET and PD patients.
- Trial name
- NCT01940406
- Testing
- Stimulation procedure
- Where
- Israel
- Sponsor
- BlueWind Medical
Parkinson's Disease
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
This is a multicenter, parallel-group, rater-blinded, randomized clinical study in subjects with advanced PD investigating the efficacy, PK, safety and tolerability of continuous SC infusion of 2 dosing regimens of ND0612H, a…
- Trial name
- NCT02577523
- Testing
- ND0612 (Levodopa/Carbidopa solution), ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
- Where
- 11 sites in United States, Austria and 2 more
- Volunteers
- 38 people
- Sponsor
- NeuroDerm Ltd.
Parkinson Disease (PD)
Safety and Usability of the Cionic Neural Sleeve for Parkinson's Disease
This research will investigate the safety and usability of the Cionic Neural Sleeve Multistim System for Parkinson's Disease.
- Trial name
- NCT07284823
- Testing
- Cionic Neural Sleeve Multistim System
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Cionic, Inc.
Parkinson's Disease (PD)
A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease
The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications.
- Trial name
- NCT07647614
- Testing
- 60 milligrams of ENERGI-F705 Tablets, 120 milligrams of ENERGI-F705 Tablets
- Where
- 2 sites in Taiwan
- Volunteers
- 105 people
- Sponsor
- Energenesis Biomedical Co., Ltd.
Heart Failure, Myocardial Infarction
A Multinational Trial To Evaluate The Parachute Implant System
The primary objective is to assess the safety of the CardioKinetix Parachute Implant and Delivery System in the partitioning of the left ventricle in patients with heart failure due to ischemic heart disease.
- Trial name
- PARACHUTE (NCT01286116)
- Testing
- Parachute Implant
- Where
- 13 sites in France, Germany and 6 more
- Volunteers
- 59 people
- Sponsor
- CardioKinetix, Inc
Parkinson Disease
Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study
This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.
- Trial name
- NCT07522606
- Testing
- BIA 28-6156
- Where
- 36 sites in United States, Italy and 3 more
- Sponsor
- Bial R&D Investments, S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.